Patents by Inventor Gérard Lambeau

Gérard Lambeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROFILING OF IMMUNODOMINANT PLA2R1 EPITOPES AS A PROGNOSIS AND PREDECTIVE FACTOR IN MEMBRANOUS NEPHROPATHY
    Publication number: 20230204602
    Abstract: The invention relates to a method for predicting the prognosis of a patient suffering from membranous nephropathy and for determining the likelihood of response to immunosuppressive treatment, based on the analysis of PLA2R1 epitope immunodomi-nance profiling.
    Type: Application
    Filed: May 17, 2021
    Publication date: June 29, 2023
    Inventors: Joana JUSTINO, Gérard LAMBEAU
  • Methods and kits for monitoring membranous nephropathy
    Patent number: 10670597
    Abstract: An in vitro method can diagnose membranous nephropathy patient. The method includes detecting in a biological sample obtained from the patient one or more autoantibodies recognizing a Thrombospondin, Type I. Domain Containing 7A (THSD7A) protein.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 2, 2020
    Assignee: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Gerard Lambeau, Nicola M. Tomas, Barbara Seitz-Polski, Rolf A. K. Stahl
  • METHODS AND KITS FOR MONITORING MEMBRANOUS NEPHROPATHY
    Publication number: 20180356417
    Abstract: An in vitro method can diagnose membranous nephropathy patient. The method includes detecting in a biological sample obtained from the patient one or more autoantibodies recognizing a Thrombospondin, Type I. Domain Containing 7A (THSD7A) protein.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Applicant: EUROIMMUN Medizinische Labordiagnostika AG
    Inventors: Gerard LAMBEAU, Nicola M. Tomas, Barbara Seitz-Polski, Rolf A.K. Stahl
  • Methods and kits for monitoring membranous nephropathy
    Patent number: 10107810
    Abstract: The present invention relates to the protein THSD7A (Thrombospondin, Type I, Domain Containing 7A) as a biomarker autoantigen in membranous nephropathy, particularly idiopathic membranous nephropathy. The invention provides diagnostic, prognostic and monitoring methods for membranous nephropathy in a patient based on the detection of autoantibodies recognizing the THSD7A protein (anti-THSD7A autoantibodies) and associated kits. The invention also provides diagnostic methods and kits based on the detection of the THSD7A level. The invention further provides therapeutic methods for membranous nephropathy.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 23, 2018
    Assignee: Euroimmun Medizinische Labordiagnostika AG
    Inventors: Gerard Lambeau, Nicola M. Tomas, Barbara Seitz-Polski, Rolf A. K. Stahl
  • METHODS AND KITS FOR MONITORING MEMBRANOUS NEPHROPATHY
    Publication number: 20170219580
    Abstract: The present invention relates to the protein THSD7A (Thrombospondin, Type I, Domain Containing 7A) as a bio-marker autoantigen in membranous nephropathy, particularly idiopathic membranous nephropathy. The invention provides diagnostic, prognostic and monitoring methods for membranous nephropathy in a patient based on the detection of autoantibodies recognizing the THSD7A protein (anti-THSD7A autoantibodies) and associated kits. The invention also provides diagnostic methods and kits based on the detection of the THSD7A level. The invention further provides therapeutic methods for membranous nephropathy.
    Type: Application
    Filed: July 23, 2015
    Publication date: August 3, 2017
    Applicant: Euroimmun Medizinische Labordiagnostika AG
    Inventors: Gerard LAMBEAU, Nicola M. TOMAS, Barbara SEITZ-POLSKI, Rolf A.K. STAHL
  • Anti-sPLA2-IIA antibodies and uses thereof
    Patent number: 9637553
    Abstract: The present invention relates to antibodies anti-sPLA2-IIA and uses thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: May 2, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • NOVEL ANTIBODIES ANTI-sPLA2-IIA AND USES THEREOF
    Publication number: 20150086564
    Abstract: The present invention relates to antibodies anti-sPLA2-IIA and uses thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 26, 2015
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • ANTIBODIES ANTI-SPLA2-X AND USES THEREOF
    Publication number: 20140370030
    Abstract: The present invention relates to isolated antibodies against human sPLA2-X and uses thereof.
    Type: Application
    Filed: December 6, 2012
    Publication date: December 18, 2014
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • ANTI-SPLA2-V ANTIBODIES AND USES THEREOF
    Publication number: 20140356379
    Abstract: The present disclosure relates to isolated antibodies against human SPLA2-V and uses thereof.
    Type: Application
    Filed: October 10, 2012
    Publication date: December 4, 2014
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • Fertilization modulation compounds and process for implementing them
    Patent number: 8758746
    Abstract: This invention relates to fertilization modulation compounds and process for implementing them.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: June 24, 2014
    Assignees: Universite Joseph Fourier, Centre National de la Recherche Scientifique
    Inventors: Christophe Arnoult, Michel De Waard, Gerard Lambeau
  • PLA2R1 AS ANTI-TUMORAL COMPOUND AND AS BIOMARKER FOR THE DETECTION OF CANCER
    Publication number: 20140155470
    Abstract: Compositions comprising a polynucleotide of human PLA2R1, a polypeptide of human PLA2R1 or an extracellular fragment of human PLA2R1 for use in the treatment of cancer in particular breast cancer, pancreatic cancer, colorectal cancer, kidney cancer and melanoma.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 5, 2014
    Inventors: David Bernard, Arnaud Augert, Gerard Lambeau, Christophe Girard, David Vindrieux
  • Methods of diagnosing a plasmodium infection
    Patent number: 8709741
    Abstract: The present disclosure provides in vitro methods of diagnosing a Plasmodium infection in a subject. The methods include measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in a blood sample from the subject. The disclosure also relates to a kit for carrying out the disclosed methods and pharmaceutical compositions comprising a recombinant mammalian GIIF, GV or GX sPLA2, or a combination thereof.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: April 29, 2014
    Assignees: Centre National de la Recherche Scientifique, Universite de Nice Sophia Antipolis, Museum National d'Histoire Naturelle
    Inventors: Christiane Deregnaucourt, Gérard Lambeau, Carole Guillaume, Joseph Schrevel
  • DIAGNOSTICS FOR MEMBRANOUS NEPHROPATHY
    Publication number: 20130280738
    Abstract: The invention provides immunoassays for detecting serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R) and uses thereof for diagnosis and prognosis evaluation of idiopathic membranous nephropathy (MN).
    Type: Application
    Filed: July 3, 2013
    Publication date: October 24, 2013
    Inventors: David J. Salant, Laurence H. Beck, Gerard Lambeau
  • Diagnostics for membranous nephropathy
    Patent number: 8507215
    Abstract: The invention provides immunoassays for detecting serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R) and uses thereof for diagnosis and prognosis evaluation of idiopathic membranous nephropathy (MN).
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: August 13, 2013
    Assignees: Boston Medical Center Corporation, Le Centre National de la Recherche Scientifique
    Inventors: David J Salant, Laurence H. Beck, Gerard Lambeau
  • METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20120311728
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a group X sPLA2 polypeptide for use in the treatment of atherosclerosis.
    Type: Application
    Filed: November 5, 2010
    Publication date: December 6, 2012
    Inventors: Ziad Mallat, Gerard Lambeau
  • Use of Secreted Phospholipases A2 in the Diagnosis and Treatment of Malaria
    Publication number: 20120282238
    Abstract: The present invention relates to an in vitro method of diagnosis of a Plasmodium infection in a subject, by measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in said subject, from a blood sample. It also relates to a kit for carrying out said method and pharmaceutical compositions comprising a recombinant mammal GIIF, GV or GX sPLA2 or a combination thereof.
    Type: Application
    Filed: December 3, 2010
    Publication date: November 8, 2012
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, MUSEUM NATIONAL D'HISTOIRE NATURELLE, UNIVERSITE DE NICE SOPHIA ANTIPOLIS
    Inventors: Christiane Deregnaucourt, Gérard Lambeau, Carole Guillaume, Joseph Schrevel
  • FERTILIZATION MODULATION COMPOUNDS AND PROCESS FOR IMPLEMENTING THEM
    Publication number: 20120034204
    Abstract: This invention relates to fertilization modulation compounds and process for implementing them.
    Type: Application
    Filed: March 24, 2010
    Publication date: February 9, 2012
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE JOSEPH FOURIER
    Inventors: Christophe Arnoult, Michel De Waard, Gerard Lambeau
  • DIAGNOSTICS FOR MEMBRANOUS NEPHROPATHY
    Publication number: 20110177534
    Abstract: The invention relates to immunoassays, reagents, therapeutics and methods of diagnosing and prognosis evaluation of idiopathic membranous nephropathy (MN). Immunoassays comprise enzyme-linked immunoabsorbent assays and nephelometric immunoassays for serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R). Therapeutic methods include removal of the auto-antibodies by absorbance or administration of soluble PLA2R or fragments to sequester the auto-antibodies.
    Type: Application
    Filed: January 14, 2011
    Publication date: July 21, 2011
    Applicants: BOSTON MEDICAL CENTER CORPORATION, LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David J. SALANT, Laurence H. BECK, Gerard LAMBEAU
  • Compositions and methods for the inhibition of phospholipase A2
    Publication number: 20080031951
    Abstract: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.
    Type: Application
    Filed: December 22, 2006
    Publication date: February 7, 2008
    Inventors: Gilles Guichard, Gersande Lena, Pascal Muller, Didier Rognan, Eric Boilard, Gerard Lambeau
  • Mammalian secreted group III phospholipase A2
    Patent number: 6875599
    Abstract: The present invention concerns DNA and peptide sequence encoding a mammalian secreted group III sPLA2 and more particularly a human secreted group III (hGIII) sPLA2. The invention also concerns the use of this secreted group III sPLA2 in methods for screening various chemical compounds.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: April 5, 2005
    Assignee: Centre National de la Recherche Scientifique - CNRS
    Inventors: Michel Lazdunski, Gérard Lambeau, Emmanuel Valentin